Medexus Pharmaceuticals (TSE:MDP) Stock Rating Lowered by Stifel Nicolaus

Stifel Nicolaus lowered shares of Medexus Pharmaceuticals (TSE:MDP - Free Report) from a buy rating to a hold rating in a research report sent to investors on Friday,BayStreet.CA reports. The brokerage currently has C$3.45 price target on the stock, down from their previous price target of C$6.00.

Several other analysts have also issued reports on MDP. Ventum Cap Mkts raised Medexus Pharmaceuticals to a "strong-buy" rating in a report on Friday, January 17th. Ventum Financial raised their target price on shares of Medexus Pharmaceuticals from C$5.00 to C$6.25 and gave the company a "buy" rating in a report on Thursday, January 30th. Raymond James raised shares of Medexus Pharmaceuticals from an "outperform" rating to a "strong-buy" rating and set a C$4.00 price target for the company in a report on Wednesday, January 8th. Alliance Global Partners raised shares of Medexus Pharmaceuticals to a "strong-buy" rating in a research note on Monday, December 23rd. Finally, Leede Financial upgraded Medexus Pharmaceuticals from a "moderate buy" rating to a "strong-buy" rating in a research note on Wednesday, January 22nd. Two investment analysts have rated the stock with a hold rating, one has assigned a buy rating and four have assigned a strong buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of "Buy" and a consensus target price of C$5.49.

Medexus Pharmaceuticals Stock Performance

Shares of TSE MDP traded up C$0.06 during midday trading on Friday, reaching C$3.19. The company's stock had a trading volume of 42,181 shares, compared to its average volume of 192,311. The company has a market cap of C$78.25 million, a P/E ratio of 63.80 and a beta of 1.96. Medexus Pharmaceuticals has a fifty-two week low of C$1.47 and a fifty-two week high of C$5.56. The business's 50 day moving average price is C$3.54 and its two-hundred day moving average price is C$2.83.

Medexus Pharmaceuticals Company Profile

Medexus Pharmaceuticals Inc operates as a specialty pharmaceutical company in Canada and the United States. The company focuses on the therapeutic areas comprising oncology, hematology, rheumatology, auto-immune diseases, allergy, and dermatology. Its primary products are IXINITY, an intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with hemophilia B; Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis and other auto-immune diseases; Rupall, a prescription allergy medication; and Gleolan, an optical imaging agent indicated in patients with glioma as an adjunct for the visualization of malignant tissue during surgery.